UCB/Celltech Merger Nears Completion: Integration To Commence Under CEO Doliveux
This article was originally published in The Pink Sheet Daily
Executive Summary
Celltech's TNF inhibitor CDP-870 is crown jewel of $2.7 bil. acquisition; a BLA filing is expected in 2007. UCB CEO Roch Doliveux will continue to serve as chief executive, while Celltech CEO Goran Ando will become deputy CEO.